**Likely Past Epidemic Peak but Influenza Activity Still Elevated in BC**

In week 11 (March 13 to 19, 2016), influenza activity continued to decline in BC, suggesting that the epidemic peak has likely passed. Most surveillance indicators showed stable or decreasing trends, although influenza-like illness activity levels remained elevated. Influenza A(H1N1)pdm09 was again the predominant circulating influenza virus in week 11.

At the BCCDC Public Health Laboratory, influenza positivity decreased from a peak of 45% in week 6 to 28% in week 11. A(H1N1)pdm09 viruses comprised about 60% of influenza detections with known type/subtype, with co-circulation of influenza B viruses.

Since our last bulletin one week ago, one new influenza A (subtype pending) outbreak was reported from a long-term care facility in FHA in week 11.

Medical Services Plan (MSP) claims for influenza illness remained higher than expected for this time of year, although current activity levels are lower than earlier historical peak levels observed in previous seasons. Sentinel ILI rates remained elevated in week 11 but were within the 10-year historical average for this time of year.
British Columbia

Sentinel Physicians

The proportion of patients with influenza-like illness (ILI) among those presenting to sentinel sites remained stable at 0.46% in week 11 and was within the 10-year historical average for this time of year. So far, 54% of sentinel sites have reported for week 11.

BC Children’s Hospital Emergency Room

The proportion of visits to BC Children’s Hospital Emergency Room (ER) attributed to ILI continued a downward trend since week 6 and was 16% in week 11, consistent with the 5-year historical average for this time of year.

Source: BCCH Admitting, Discharge, Transfer database (ADT). Data includes records with a triage chief complaint of "flu" or "influenza" or "fever/cough."
* 5-year historical average for 2015-16 season based on 2010-11 to 2014-15 seasons; CI=confidence interval
BC Medical Services Plan (MSP) general practitioner claims for influenza illness (II), as a proportion of all submitted MSP claims, showed signs of gradual decline in most regions of the province in week 11, except in VIHA where an increase was observed. Rates remained higher than expected for this time of year but were lower than historical peak levels observed in previous seasons, which typically occur earlier in the season. In week 11, rates were above 10-year 75th percentiles in all Health Authorities and for the province overall, with the exception of FHA where rates were between 25th and 75th percentiles.

Service claims submitted to MSP for influenza illness (II)* as a proportion of all submitted general practitioner service claims, British Columbia, 2015-16

Data for the period August 1, 2009 to July 31, 2010 have been excluded from the 10-year median calculation due to atypical seasonality during the 2009/2010 H1N1 pandemic year. MSP week beginning August 1, 2015 corresponds to sentinel ILI week 30; data are current to March 22, 2016.

Data provided by Population Health Surveillance and Epidemiology, BC Ministry of Health Services.

* Influenza illness is tracked as the percentage of all submitted MSP general practitioner claims with ICD-9 code 487 (influenza).
Laboratory Reports

BCCDC Public Health Laboratory

In week 11, 368 patients were tested for respiratory viruses at the BCCDC Public Health Laboratory (PHL). Of these, 104 (28%) tested positive for influenza, including 72 (69%) with influenza A [53 A(H1N1)pdm09, 2 A(H3N2), and 17 subtype pending] and 32 (31%) with influenza B. Influenza positivity continued a decreasing trend from a peak of 45% in week 6 to 28% in week 11. Since week 9, influenza A(H1N1)pdm09 has been the predominant circulating influenza virus detected at the BCCDC PHL, comprising about 60% of influenza detections with known type/subtype in week 11. Respiratory syncytial viruses (RSV) and rhino/enteroviruses were also commonly detected during this period.

Cumulatively since week 40 (starting October 4, 2015), 1850 (27%) patients have tested positive for influenza at the BCCDC PHL, including 980 (53%) with influenza A [686 A(H1N1)pdm09, 273 A(H3N2), and 21 subtype pending], 866 (47%) with influenza B, and four adult patients with influenza A and B co-infections. The 2015-16 season to date has been characterized by mixed circulation of influenza A and B viruses, with A(H1N1)pdm09 subtype viruses predominating over A(H3N2) subtype viruses since week 2 among influenza A detections and B/Victoria lineage viruses predominating over B/Yamagata lineage viruses among influenza B detections.

So far this season (cumulatively since week 40), just over one-half (52%) of influenza detections have been in non-elderly, working-aged adults 20-64 years, with a smaller proportion of detections in children <20 years (27%) and elderly adults ≥65 years (21%). However, this age distribution differs by influenza type/subtype: adults 20-64 years, and to a lesser extent children <20 years, comprise a larger proportion of A(H1N1)pdm09 and influenza B cases, while elderly adults ≥65 years comprise a larger proportion of A(H3N2) cases.

Influenza and other virus detections among respiratory specimens submitted to BCCDC Public Health Laboratory, 2015-16

Data are current to March 23, 2016.
Cumulative number (since week 40) of influenza detections by type/subtype and age group,
BCCDC Public Health Laboratory, 2015-16

Data are current to March 23, 2016; figure includes cumulative influenza detections for specimens collected from weeks 40-11.

Age distribution of influenza detections (cumulative since week 40) by type/subtype,
BCCDC Public Health Laboratory, 2015-16

Data are current to March 23, 2016; figure includes cumulative influenza detections for specimens collected from weeks 40-11.
BC Children’s and Women’s Health Centre Laboratory

In week 11, the BC Children’s and Women’s Health Centre Laboratory conducted 104 tests for influenza; 14 (13%) were positive for influenza A, and 3 (3%) were positive for influenza B. Respiratory syncytial virus (RSV) continued to be the predominant respiratory virus detected in week 10 (20% of tests for RSV were positive).

* Positive rates were calculated using aggregate data. The denominators for each rate represent the total number of tests; multiple tests may be performed for a single specimen and/or patient.
Influenza-like Illness (ILI) Outbreaks

Since our last bulletin one week ago, one new lab-confirmed influenza A (subtype pending) outbreak was reported from a long-term care facility (LTCF) in FHA with onset in week 11. No new ILI outbreaks in schools were reported in week 11 on account of the spring break holiday.

In total since mid-August (since week 32, starting August 9, 2015), 29 influenza outbreaks have been reported from facilities, including 27 from LTCFs, one from an acute care facility, and one from a rehabilitation facility:

- 16 with influenza A(H3N2) detected;
- 1 with influenza A(H1N1)pdm09 detected;
- 1 with influenza A (subtype pending) detected;
- 2 with both influenza A(H3N2) and A(H1N1)pdm09 detected;
- 2 with both influenza A(H3N2) and B detected; and
- 7 with influenza B detected.

Thirty-seven school ILI outbreaks have been reported so far this season.

Updated AMMI Guidelines: LTCF Outbreak Control

In December 2015, the Association of Medical Microbiology and Infectious Disease (AMMI) Canada posted updated recommendations for influenza antiviral drug treatment and prophylaxis for the 2015-16 season, notably in relation to control of influenza outbreaks in long-term care facilities, available from [www.ammi.ca/guidelines](http://www.ammi.ca/guidelines).
National

FluWatch (week 11, March 13-19, 2016)
Overall in week 11, influenza activity remained near its peak, but had begun to decrease across Canada. Nearly all reporting regions reported sporadic or localized activity. For the first time since week 49 of 2015, the percentage of tests positive for influenza decreased, from 36% in week 10 to 31% in week 11, still above the five-year expected levels for this time of year (range: 12-19%). However, with the late start to the 2015-16 influenza season, these above-normal levels are not unexpected and are typical of peak season levels. Influenza A(H1N1)pdm09 remains the most common influenza subtype circulating in Canada. In week 11, adults 65 years and older accounted for the largest proportion of hospitalizations. Paediatric hospitalizations reported by the IMPACT network dropped from the previous week, totalling 93 in week 11. The number of outbreaks reported in week 11 decreased sharply from the previous week, with three-quarters of the outbreaks reported in long-term care facilities. Details are available at: healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/surveillance/fluwatch-reports-rapports-surveillance-influenza-eng.php.

National Microbiology Laboratory (NML): Strain Characterization
From September 1, 2015 to March 24, 2016, the National Microbiology Laboratory (NML) received 1246 influenza viruses [149 A(H3N2), 775 A(H1N1)pdm09 and 322 B] from Canadian laboratories for antigenic characterization.

Influenza A(H3N2): Of the 149 influenza A(H3N2) viruses, only 35 (23%) had sufficient haemagglutination titre for antigenic characterization by haemagglutination inhibition (HI) assay. Of the 35 viruses characterized by HI assay, all were considered antigenically similar to cell-passaged A/Switzerland/9715293/2013, the WHO-recommended A(H3N2) component for the 2015-16 northern hemisphere influenza vaccine. Genetic characterization was performed to infer antigenic properties on the remaining 114 viruses that did not grow to sufficient haemagglutination titre for HI assay. Of the 114 A(H3N2) viruses genetically characterized, all were reported to belong to a genetic group in which most viruses were antigenically related to A/Switzerland/9715293/2013.

Influenza A(H1N1)pdm09: The 775 A(H1N1)pdm09 viruses characterized were antigenically similar to A/California/7/2009, the WHO-recommended A(H1N1) component for the 2015-16 northern hemisphere influenza vaccine.

Influenza B: Of the 322 influenza B viruses characterized, 90 (28%) were antigenically similar to B/Phuket/3073/2013 (Yamagata lineage), the recommended influenza B component for the 2015-16 northern hemisphere influenza vaccine, while 232 (72%) were characterized as B/Brisbane/60/2008 (Victoria lineage), the recommended influenza B component for the 2015-16 northern hemisphere quadrivalent influenza vaccine containing two influenza B components.

National Microbiology Laboratory (NML): Antiviral Resistance
From September 1, 2015 to March 24, 2016, the NML received influenza viruses from Canadian laboratories for drug susceptibility testing. Of the 801 influenza A viruses [150 A(H3N2) and 651 A(H1N1)pdm09] tested against amantadine, all were resistant with the exception of one A(H3N2) virus which was sensitive to amantadine. Of the 826 influenza viruses [134 A(H3N2), 479 A(H1N1)pdm09 and 213 B] tested against oseltamivir, all A(H3N2) and B viruses and 472/479 (99%) A(H1N1)pdm09 viruses were sensitive; seven A(H1N1)pdm09 viruses with a H275Y mutation were resistant. Of the 826 influenza viruses [134 A(H3N2), 479 A(H1N1)pdm09 and 213 B] tested against zanamivir, all were sensitive.
International

USA (week 10, March 6-12, 2016)

During week 10, influenza activity increased in the United States. The most frequently identified influenza virus type reported by public health laboratories during week 10 was influenza A, with influenza A(H1N1)pdm09 viruses predominating. The percentage of respiratory specimens testing positive for influenza in clinical laboratories increased. The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic thresholds. Eight influenza-associated paediatric deaths were reported. A cumulative rate for the season of 14.5 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The proportion of outpatient visits for influenza-like illness (ILI) was 3.7%, which is above the national baseline of 2.1%. The geographic spread of influenza in 40 states was reported as widespread, and 10 states reported regional activity. Details are available at: www.cdc.gov/flu/weekly/.

WHO (March 21, 2016)

Globally, high levels of influenza activity continued to be reported. In North America, influenza activity continued to increase and acute respiratory illness (ARI) and pneumonia activity were above thresholds in Mexico. In some countries in northern Europe, influenza B virus detections were increasing. In Northern Temperate Asia, influenza activity was ongoing with increasing levels of influenza B virus.

- In North America, Mexico reported above expected levels of ARI and pneumonia activity during this period. Increasing influenza activity predominantly due to influenza A(H1N1)pdm09 virus continued to be reported in Canada and USA.
- In northern and south west Europe, influenza detections continued to remain high with increasing activity of influenza B virus. In Eastern Europe, influenza activity and severe acute respiratory illness (SARI) activity seemed to have peaked.
- In Northern Temperate Asia, influenza activity was ongoing with influenza B activity predominating.
- In Western Asia, influenza activity continued to decrease. Oman reported ongoing low levels of influenza A(H1N1)pdm09 and influenza B activity.
- In South East Asia, ongoing influenza activity was reported during this period with predominantly influenza B detections.
- In tropical countries of the Americas, Central America and the Caribbean, influenza and other respiratory virus activity were overall at low levels. In Jamaica however, SARI activity remained high with influenza A(H1N1)pdm09 predominating while high RSV activity was reported in Ecuador.
- In the temperate countries of the Southern Hemisphere, influenza virus activity remained low.

From February 22 to March 6, 2016, the WHO GISRS laboratories tested more than 159,429 specimens, of which 47,202 were positive for influenza viruses: 35,026 (74%) were typed as influenza A and 12,176 (26%) as influenza B. Of the sub-typed influenza A viruses, 15,851 (87%) were influenza A(H1N1)pdm09 and 2,300 (13%) were influenza A(H3N2). Of the characterized B viruses, 588 (25%) belonged to the B/Yamagata lineage and 1747 (75%) to the B/Victoria lineage.

Details are available at: www.who.int/influenza/surveillance_monitoring/updates/en/.

On February 8, 2016, the WHO published a Risk Assessment on Seasonal Influenza A(H1N1)pdm09, available from: www.who.int/influenza/publications/riskassessment_AH1N1pdm09_201602/en/.
WHO Recommendations for Influenza Vaccines

WHO Recommendations for 2016-17 Northern Hemisphere Influenza Vaccine
On February 25, 2016, the WHO announced recommended strain components for the 2016-17 Northern Hemisphere trivalent influenza vaccine (TIV): *

- an A/California/7/2009 (H1N1)pdm09-like virus;†
- an A/Hong Kong/4801/2014(H3N2)-like virus;‡
- a B/Brisbane/60/2008-like (Victoria-lineage) virus.§

It is recommended that quadrivalent influenza vaccines (QIV) containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like (Yamagata-lineage) virus.

These recommended components are the same as those recommended for the 2016 Southern Hemisphere vaccine.

* Recommended strains represent a change for two of the three components used for the 2015-16 Northern Hemisphere vaccines.
† Recommended strain has been retained as the A(H1N1) component since the 2009 pandemic and has been included in the Northern Hemisphere vaccine since 2010-11.
‡ Recommended strain for the A(H3N2) component represents a phylogenetic clade-level change from a clade 3C.3a virus to a clade 3C.2a virus.
§ Recommended strain for the influenza B component represents a lineage-level change from a B/Yamagata-lineage virus to a B/Victoria-lineage virus.


WHO Recommendations for 2015-16 Northern Hemisphere Influenza Vaccine
On February 26, 2015, the WHO announced the recommended strain components for the 2015-16 Northern Hemisphere trivalent influenza vaccine (TIV): *

- an A/California/7/2009(H1N1)pdm09-like virus;†
- an A/Switzerland/9715293/2013(H3N2)-like virus;‡
- a B/Phuket/3073/2013-like (Yamagata-lineage) virus.§

It is recommended that quadrivalent influenza vaccines (QIV) containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like (Victoria-lineage) virus.

* These recommended strains are the same as those used for the 2015 Southern Hemisphere vaccine.
† Recommended strain has been retained as the A(H1N1) component since the 2009 pandemic and has been included in the Northern Hemisphere vaccine since 2010-11.
‡ A/South Australia/55/2014, A/Norway/466/2014, and A/Stockholm/6/2014 are A/Switzerland/9715293/2013-like viruses. Recommended strain is considered antigenically distinct from the A/Texas/50/2012-like virus recommended for the 2014-15 Northern Hemisphere vaccine and clusters within the emerging phylogenetic clade 3C.3a.
§ Recommended strain is the same influenza B-Yamagata lineage as the B/Massachusetts/2/2012-like virus recommended for the 2014-15 Northern Hemisphere vaccine but represents a phylogenetic clade-level change from clade 2 to clade 3.

For further details: www.who.int/influenza/vaccines/virus/recommendations/2015_16_north/en/.
Additional Information

Explanatory Note:
The surveillance period for the 2015-16 influenza season is defined starting in week 40. Weeks 36-39 of
the 2014-15 season are shown on graphs for comparison purposes.

List of Acronyms:
- ACF: Acute Care Facility
- AI: Avian influenza
- FHA: Fraser Health Authority
- HBoV: Human bocavirus
- HMPV: Human metapneumovirus
- HSDA: Health Service Delivery Area
- IHA: Interior Health Authority
- ILI: Influenza-Like Illness
- LTCF: Long-Term Care Facility
- MSP: BC Medical Services Plan
- NHA: Northern Health Authority
- NML: National Microbiological Laboratory
- A(H1N1)pdm09: Pandemic H1N1 influenza (2009)
- RSV: Respiratory syncytial virus
- VCHA: Vancouver Coastal Health Authority
- VIHA: Vancouver Island Health Authority
- WHO: World Health Organization

Current AMMI Canada Guidelines on the Use of Antiviral Drugs for Influenza:
www.ammi.ca/guidelines

Web Sites:
- BCCDC Emerging Respiratory Pathogen Updates:
  www.bccdc.ca/health-professionals/data-reports/emerging-respiratory-virus-updates
- Influenza Web Sites
  Canada – Flu Watch: www.phac-aspc.gc.ca/fluwatch/
  USA Weekly Surveillance Reports: www.cdc.gov/flu/weekly/
  European Influenza Surveillance Scheme:
  ecdc.europa.eu/EN/HEALTHTOPICS/SEASONAL_INFLUENZA/EPIDEMIOLOGICAL_DATA/Pages/Weekly_Influenza_Surveillance_Overview.aspx
  WHO – Weekly Epidemiological Record: www.who.int/wer/en/
  WHO Collaborating Centre for Reference and Research on Influenza (Australia):
  www.influenzacentre.org/
  Australian Influenza Report:
- Avian Influenza Web Sites
  World Organization for Animal Health: www.oie.int/eng/en_index.htm

Contact Us:
Tel: (604) 707-2510
Fax: (604) 707-2516
Email: InfluenzaFieldEpi@bccdc.ca

Communicable Disease Prevention and Control Services (CDPACS)
BC Centre for Disease Control
655 West 12th Ave, Vancouver BC V5Z 4R4

Online: www.bccdc.ca/health-professionals/data-reports/influenza-surveillance-reports
Influenza-Like Illness (ILI) Outbreak Summary Report Form

Please complete and email to ilioutbreak@bccdc.ca

Note: This form is for provincial surveillance purposes. Please notify your local health unit per local guidelines/requirements.

**ILI**: Acute onset of respiratory illness with fever and cough and with one or more of the following: sore throat, arthralgia, myalgia, or prostration which could be due to influenza virus. In children under 5, gastrointestinal symptoms may also be present. In patients under 5, 65 and older, fever may not be prominent.

**Schools and work site outbreak**: greater than 10% absenteeism on any day, most likely due to ILI.

**Residential institutions (facilities) outbreak**: two or more cases of ILI within a seven-day period.

<table>
<thead>
<tr>
<th>Reporting Information</th>
<th>Health unit/medical health officer notified? □ Yes □ No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person Reporting:</td>
<td>______________________</td>
</tr>
<tr>
<td>Title:</td>
<td>______________________</td>
</tr>
<tr>
<td>Contact Phone:</td>
<td>______________________</td>
</tr>
<tr>
<td>Email:</td>
<td>______________________</td>
</tr>
<tr>
<td>Health Authority:</td>
<td>______________________</td>
</tr>
<tr>
<td>HSDA:</td>
<td>______________________</td>
</tr>
<tr>
<td>Full Facility Name:</td>
<td>_________________________________________________</td>
</tr>
</tbody>
</table>

**Is this report:**
- □ First Notification (**complete section B below; Section D if available**)
- □ Update (**complete section C below; Section D if available**)
- □ Outbreak Over (**complete section C below; Section D if available**)

**First Notification**

**Type of facility:**
- □ LTCF
- □ Acute Care Hospital
- □ Senior’s Residence
- □ Workplace
- □ School (grades: )
- □ Other (_______)

**Date of onset of first case of ILI (dd/mm/yyyy):** DD / MMM / YYYY

<table>
<thead>
<tr>
<th>Numbers to date</th>
<th>Residents/Students</th>
<th>Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ILI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Update AND Outbreak Declared Over**

**Date of onset for most recent case of ILI (dd/mm/yyyy):** DD / MMM / YYYY

If over, date outbreak declared over (dd/mm/yyyy): DD / MMM / YYYY

<table>
<thead>
<tr>
<th>Numbers to date</th>
<th>Residents/Students</th>
<th>Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ILI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Laboratory Information**

**Specimen(s) submitted?**
- □ Yes (location: _______________)
- □ No
- □ Don’t know

If yes, organism identified?
- □ Yes (specify: _______________)
- □ No
- □ Don’t know

Communicable Disease Prevention & Control Services
655 W. 12th Ave.
Vancouver BC V5Z 4R4

Phone: (604) 707-2510
Fax: (604) 707-2516
ilioutbreak@bccdc.ca